Halozyme Therapeutics, Inc. (NASDAQ:HALO) is a biopharmaceutical company focused on innovative drug delivery technologies, primarily through its Enhaze platform. This technology, based on the rHuPH20 ...

News of a big and important regulator's move was the electricity that powered Biohaven (NYSE: BHVN) stock to an 11%-plus gain on the second trading day of the week. Its leading investigational drug is ...

Oncocyte Corp (NASDAQ:OCX), a small-cap biotechnology company with a market capitalization of $39.6 million, has reported that Patrick W. Smith, a significant shareholder of the company, has recently ...

Biotech giant Biogen Inc (NASDAQ:BIIB) is scheduled to report fourth-quarter earnings on 12 February. The Wall Street ...

In a challenging year for Actinium Pharmaceuticals (NYSE:ATNM), the company's stock has touched a 52-week low, trading at $1.1, marking an 80% decline from its 52-week high of $10.24. According to ...

Biohaven stock hurdled its 50-day and 200-day lines Tuesday after the FDA granted its SCA treatment a speedier review time.

Travere Therapeutics reached an agreement Tuesday on what data the FDA would require to approve its drug for a kidney disease.

SpringWorks Therapeutics (NASDAQ:SWTX), which is reportedly in takeover talks with Merck KGaA (OTCPK:MKGAF) (OTCPK:MKKGY), has received FDA approval for the drug mirdametinib for the treatment of ...

Axsome Therapeutics (AXSM) is climbing nearly 4% after Swiss bank UBS increased its price target on the shares to $133 from ...

We recently compiled a list of the 10 Mid-Cap Stocks Insiders Are Selling Recently. In this article, we are going to take a ...

Biohaven (BHVN) is jumping 10% after the FDA agreed to review the company’s potential treatment for a rare disease. The FDA’s ...

Degrees Pharmaceuticals (SXTP) announced that the United States Food and Drug Administration does not object to the company’s plan to import ...